IP Library Granted Patent US 9,908,915
Granted Patent B2
US 9,908,915 · App. 15/036,849 · Granted Mar 6, 2018

Cell-penetrating compositions and methods using same

Inventors: William C. Sessa (Madison, CT); Frank J. Giordano (Madison, CT)
Assignee: Yale University
C07K7/06A61K47/645C07K14/4702C07K14/4703A61K38/00C07K2319/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,908,915
App. No.
15/036,849
Granted
Mar 6, 2018
Kind
B2
Abstract

An isolated transport peptide, which crosses the cell membrane of a cell and/or binds to a target cell, is described. The transport peptide can be incorporated into a transport construct in which the transport peptide is linked to a cargo moiety to be delivered into a cell. Also described herein is a method of delivering a transport construct into and/or to a cell.

Claims (25)

1. An isolated construct, or a salt or solvate thereof, comprising the transport peptide of amino acid sequence RRPPR (SEQ ID NO: 1) that is linked to a cargo moiety comprising a peptide of amino acid sequence selected from the group consisting of SEQ ID NOs: 3-6.

2. The construct of claim 1 , which is part of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

3. An isolated construct, or a salt or solvate thereof, comprising the transport peptide of amino acid sequence RRPPR (SEQ ID NO: 1) that is linked to a cargo moiety selected from the group consisting of a nucleic acid; oligosaccharide; lipid; glycolipid; lipoprotein; small molecule compound; therapeutic drug; UV-vis, fluorescent or radioactive label; imaging agent; diagnostic agent; prophylactic agent; liposome; virus; and any combinations thereof.

4. The construct of claim 1 , wherein the cargo moiety is covalently linked to the transport peptide through a linker or a chemical bond.

5. The construct of claim 4 , wherein the linker comprises a disulfide bond or wherein the chemical bond between the cargo moiety and the transport peptide comprises a disulfide bond.

6. The construct of claim 4 , wherein the transport peptide is covalently linked through an amide bond to the cargo moiety.

7. The construct of claim 1 , which comprises a peptide of amino acid sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 3; SEQ ID NO: 1-SEQ ID NO: 4; SEQ ID NO: 1-SEQ ID NO: 5; SEQ ID NO: 1-SEQ ID NO: 6; SEQ ID NO: 3-SEQ ID NO: 1; SEQ ID NO: 4-SEQ ID NO: 1; SEQ ID NO: 5-SEQ ID NO: 1; and SEQ ID NO: 6-SEQ ID NO: 1.

8. The construct of claim 1 , which is a peptide of amino acid sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 3; SEQ ID NO: 1-SEQ ID NO: 4; SEQ ID NO: 1-SEQ ID NO: 5; SEQ ID NO: 1-SEQ ID NO: 6; SEQ ID NO: 3-SEQ ID NO: 1; SEQ ID NO: 4-SEQ ID NO: 1; SEQ ID NO: 5-SEQ ID NO: 1; and SEQ ID NO: 6-SEQ ID NO: 1.

9. A method of delivering a cargo moiety to or into a target cell, the method comprising contacting the target cell with a transport construct, wherein the transport construct comprises a transport peptide of amino acid sequence RRPPR (SEQ ID NO:1) that is linked to a cargo moiety comprising a peptide of amino acid sequence selected from the group consisting of SEQ ID NOs: 3-6, whereby the cargo moiety is delivered to or into the target cell.

10. The method of claim 9 , wherein the transport peptide is covalently linked to the cargo moiety through a linker or a chemical bond.

11. The method of claim 10 , wherein the linker comprises a disulfide bond or wherein the chemical bond between the cargo moiety and the transport peptide comprises a disulfide bond.

12. The method of claim 10 , wherein the transport peptide is covalently linked through an amide bond to the cargo moiety.

13. The method of claim 9 , wherein the transport construct comprises at least one peptide of amino acid sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 3; SEQ ID NO: 1-SEQ ID NO: 4; SEQ ID NO: 1-SEQ ID NO: 5; SEQ ID NO: 1-SEQ ID NO: 6; SEQ ID NO: 3-SEQ ID NO: 1; SEQ ID NO: 4-SEQ ID NO: 1; SEQ ID NO: 5-SEQ ID NO: 1; and SEQ ID NO: 6-SEQ ID NO: 1.

14. The method of claim 9 , wherein the target cell comprises at least one selected from the group consisting of an endothelial cell, cardiac cell, immune cell, skeletal muscle cell and brain cell.

15. The method of claim 9 , wherein the cell is mammalian.

16. The method of claim 15 , wherein the mammal is human.

17. A method of delivering a cargo moiety to or into a target cell of a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a transport construct, wherein the transport construct comprises a transport peptide of amino acid sequence RRPPR (SEQ ID NO:1) that is linked to a cargo moiety comprising a peptide of amino acid sequence selected from the group consisting of SEQ ID NOs: 3-6, whereby the cargo moiety is delivered to or into the target cell of the subject.

18. The method of claim 17 , wherein the transport peptide is covalently linked to the cargo moiety through a linker or a chemical bond.

19. The method of claim 18 , wherein the linker comprises a disulfide bond or wherein the chemical bond between the cargo moiety and the transport peptide comprises a disulfide bond.

20. The method of claim 18 , wherein the transport peptide is covalently linked through an amide bond to the cargo moiety.

21. The method of claim 17 , wherein the transport construct comprises at least one peptide of amino acid sequence selected from the group consisting of SEQ ID NO: 1-SEQ ID NO: 3; SEQ ID NO: 1-SEQ ID NO: 4; SEQ ID NO: 1-SEQ ID NO: 5; SEQ ID NO: 1-SEQ ID NO: 6; SEQ ID NO: 3-SEQ ID NO: 1; SEQ ID NO: 4-SEQ ID NO: 1; SEQ ID NO: 5-SEQ ID NO: 1; and SEQ ID NO: 6-SEQ ID NO: 1.

22. The method of claim 17 , wherein the target cell comprises at least one selected from the group consisting of an endothelial cell, cardiac cell, immune cell, skeletal muscle cell and brain cell.

23. The method of claim 17 , wherein the transport construct is administered to the subject by at least one route selected from the group consisting of oral, transmucosal, topical, transdermal, intradermal, subcutaneous, ophthalmic, intravitreal, subconjunctival, suprachoroidal, intracameral, inhalational, intrabronchial, pulmonary, intravenous, intra-arterial, intraduodenal, intravesical, parenteral, intrathecal, intramuscular and intragastrical.

24. The method of claim 17 , wherein the subject is a mammal.

25. The method of claim 24 , wherein the mammal is human.

Continuity (2)
Provisional Application 61908963 · Nov 26, 2013
Related Publication 20160289269A1 · Oct 6, 2016